SARA Registry

SARA Registry
Name	SARA Registry
Type	Clinical registry
Established	2009
Headquarters	Boston, Massachusetts
Region served	International
Languages	English
Leader title	Director
Leader name	Dr. Maria A. Levin

SARA Registry

The SARA Registry is an international clinical and research registry that aggregates longitudinal patient-level data for rare and complex neuromuscular and neurodegenerative conditions. It connects hospitals, academic centers, pharmaceutical sponsors, patient advocacy organizations, and regulatory agencies to support natural history studies, clinical trial readiness, and post-market surveillance. The Registry emphasizes standardized phenotyping, interoperable data models, and multi-stakeholder governance to accelerate translational research and regulatory decision-making.

Overview

The Registry was conceived as a collaborative platform bringing together stakeholders such as National Institutes of Health, European Medicines Agency, Food and Drug Administration, World Health Organization, European Respiratory Society, and advocacy groups like Muscular Dystrophy Association and Rare Diseases Europe. It interfaces with clinical centers of excellence including Massachusetts General Hospital, Johns Hopkins Hospital, Queen Square, and Mayo Clinic to harmonize patient recruitment, outcome measurement, and biospecimen collection. SARA's architecture integrates standards from Health Level Seven International, terminologies used by SNOMED International and LOINC, and registry best practices promulgated by International Rare Diseases Research Consortium and European Reference Networks.

History and Development

Origins trace to multi-institutional initiatives launched after funding and policy signals from National Institutes of Health and philanthropic investments from foundations like Wellcome Trust and Bill & Melinda Gates Foundation. Early technical work incorporated electronic data capture platforms pioneered by groups at Massachusetts Institute of Technology and Stanford University, while governance frameworks borrowed from consortia connected to International Committee of Medical Journal Editors and Committee on Publication Ethics. Milestones include first pilot cohorts established with clinical partners such as Hospital for Sick Children (Toronto), expansion to include industry collaborators like Pfizer, Roche, and Novartis, and regulatory interactions with European Medicines Agency that informed post-authorization safety studies. Iterative development cycles involved patient groups including Genetic Alliance and disease-specific organizations such as Alzheimer's Association and Amyotrophic Lateral Sclerosis Association.

Scope and Enrollment

The Registry encompasses multiple disease modules spanning neuromuscular, neurodegenerative, and rare metabolic disorders. Participating sites include tertiary referral centers—Johns Hopkins Hospital, Cleveland Clinic, Charité – Universitätsmedizin Berlin—and regional hubs coordinated with organizations like European Reference Networks and national health systems such as NHS England and Canada Health Infoway. Enrollment pathways originate from clinic referrals, advocacy-driven campaigns by National Organization for Rare Disorders, and sponsor-initiated screening during clinical trials held by GlaxoSmithKline and AstraZeneca. Inclusion criteria are disease-specific; datasets capture demographics, clinical scales validated by consortia like International Neuromuscular Consortium, imaging panels referenced to standards from Radiological Society of North America, and biospecimens cataloged in biobanks tied to European Biobanking and BioMolecular resources Research Infrastructure.

Data Structure and Standards

Data architecture employs interoperable models aligned with Health Level Seven International Fast Healthcare Interoperability Resources and vocabularies from SNOMED International, LOINC, and Human Phenotype Ontology. Case report forms and electronic phenotyping use instruments validated by clinical research networks such as Clinical Data Interchange Standards Consortium and measurement anchors referenced to outcome sets from Core Outcome Measures in Effectiveness Trials. Metadata strategies adopt the Findable, Accessible, Interoperable, Reusable principles promoted by European Open Science Cloud and National Institutes of Health data-sharing policies. The Registry supports secure linkage to electronic health records at partner institutions like Partners HealthCare, and enables data exports compatible with formats used by randomized trials registered in ClinicalTrials.gov and observational platforms curated by Observational Health Data Sciences and Informatics.

Governance, Ethics, and Privacy

Governance is multi-tiered, combining technical committees, scientific advisory boards with members from American Neurological Association and European Academy of Neurology, and patient advisory councils including representatives from Genetic Alliance and disease-specific groups. Ethical oversight aligns with frameworks from Declaration of Helsinki and regulatory guidance from European Medicines Agency and Food and Drug Administration. Privacy controls implement de-identification and data minimization consistent with Health Insurance Portability and Accountability Act and General Data Protection Regulation requirements; data access committees evaluate requests from academic investigators at institutions such as University of Oxford and Harvard Medical School and industry sponsors like Bristol Myers Squibb. Consent processes incorporate dynamic consent models influenced by research at Wellcome Trust and policy recommendations from National Academies of Sciences, Engineering, and Medicine.

Research Use and Impact

The Registry has supported natural history studies cited in regulatory submissions to European Medicines Agency and Food and Drug Administration, facilitated endpoint validation studies involving consortia like International Rare Diseases Research Consortium, and enabled post-market safety surveillance for therapies developed by companies including Biogen and Vertex Pharmaceuticals. Publications arising from Registry data appear in journals such as The Lancet, New England Journal of Medicine, and Nature Medicine and inform clinical guidelines authored by societies like European Academy of Neurology and American Academy of Neurology. The platform's interoperable datasets contributed to multi-center collaborations with networks like Global Alliance for Genomics and Health and analytics partnerships with initiatives such as Observational Health Data Sciences and Informatics, accelerating drug development pipelines and improving trial design for rare disease therapeutics.

Category:Medical registries